Axsome Therapeutics price target raised to $140 from $138 at RBC Capital
RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...
BioSpace1d
Biopharma Heads to JP Morgan Seeking an M&A Spark to Improve Sentiment
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...
The Pharma Letter2d
The week in pharma: action, reaction and insight – week to January 3
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...
alzheimersnewstoday4d
Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
BioSpace5d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
Investor's Business Daily on MSN5d
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...